CMIC becomes Align Clinical CRO member to enhance trial partnerships
Category: #health  By Mateen Dalal  Date: 2019-07-11
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

CMIC becomes Align Clinical CRO member to enhance trial partnerships

The teaming up of CMIC with other companies will improve the collaboration and execution of clinical studies

CMIC Group, a leading Japanese Contract Research Organization (CRO) that provides complete range of pharmaceutical drug services, recently announced that it has joined Align Clinical CRO, an industry standards group for life sciences aimed at creating open tech standards that make it easier for CROs and sponsors to work together during trials.

Apparently, CMIC brings over 25 years of experience as a solution provider and operational expertise in clinical trial in Asia and is the first CRO from Japan to join the group. CMIC is teaming up with major CROs partners for the improvement of collaboration and execution during clinical studies.

CMIC is known as a strategic partner that helps sponsors in the rapid development of better medicines with solutions ranging from the development of drug to manufacturing, along with filing to post marketing surveillance.

CMIC HOLDINGS Co., Ltd.’s COO and President Keiko Oishi said that global healthcare sector  is witnessing a significant change. There is an increase in the number of global trials, the study designs are more complex, and the qualification requirements and the kind of service requests are changing as well. Being the member of Align Clinical CRO, the company is committed towards helping the industry increase productivity, run clinical trials efficiently and reduce the operational costs.

For the uninitiated, CMIC started business as the first CRO in Japan in 1992 and today, it provides comprehensive support services for the development of pharmaceutical products, manufacturing and sales and marketing of those products. The company also manages the healthcare business sector and develops as well as sells diagnostic orphan and pharmaceutical drugs, responding to the diversifying needs.

Based on CMIC Group’s accumulated knowledge and experience as a CRO pioneer, the company has developed a business model which is called Pharmaceutical Value Creator (PVC). The PVC is used by the company to create new value in the field of healthcare.

Source Credit- https://www.cmicgroup.com/e/news/20190710

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...

Tata Motors records 25% jump in global sales in second quarter of 2021

Tata Motors records 25% jump in global sales in second quarter of 2021

By Mateen Dalal

The automaker’s annual wholesale growth has been around 24%. The company saw a 10% rise in passenger car sales during Q2 2021, as compared to the same period in 2020. Tata Motors Limited reported substantial growth in Q2 2021, with its glo...